Krystian Jazdzewski MD, PhD


Krystian Jazdzewski MD, PhD
Res Asst ProfessorCollege of Medicinejazdzewski.1@osu.edu
850 Biomedical Research Tower 460 W 12th Avenue Columbus Ohio 43210
Phone:614-688-8002Fax: (614) 688-4114
  • Molecular Biology and Cancer Genetics

General Research Interest

Cancer Genetics and Genomics. The role of microRNA variations in thyroid cancer predisposition and tumorigenesis.

Research Description

The evolving awareness of microRNAs (miRs) and other non-coding RNA genes was beginning to hint that miRs might be responsible for some of the strong genetic predisposition displayed by thyroid cancer. Dr. Jazdzewski performed genetic association studies that clearly suggested such a role for miR-146a. The study, designed to determine the mechanism involved, produced exciting results, as it showed that the rare allele in the polymorphism of pre-miR-146a has almost totally lost the ability to produce mature miR. Moreover, 4.7% of tumors had undergone somatic mutations of the SNP sequence. Thus, Dr. Jazdzewski’s data showed that a common polymorphism in microRNA gene affects the miR expression, contributes to the genetic predisposition to thyroid cancer, and plays a role in the tumorigenesis through somatic mutation (PNAS, 2008). The miR-146a proved to be the first gene predisposing to papillary thyroid carcinoma focusing attention of the field on the role of non-coding RNA genes in thyroid tumorigenesis. Dr. Jazdzewski continued his research on microRNA genes and made another discovery: that an “innocent” genomic alteration such as a SNP when located in the pre-miR sequence can lead to the production of 2 miRs, each with its distinct set of target genes (PNAS, 2009). The realization that this can occur carries potentially far-reaching consequences for our understanding of what miRs do and underscores the role of variations within miR sequence. In his recent work Dr. Jazdzewski addressed the functional consequences of the upregulation of microRNA genes found in thyroid cancer. Dr. Jazdzewski’s group queried what genes were regulated by those miRs that were overexpressed in thyroid tumors and, surprisingly, noticed that the top seven miRs deregulated in thyroid tumors were predicted to bind to the same single gene, namely THRB, a known tumor-supressor gene. In further experiments they proved that an up-regulation of microRNAs might well be an important mechanism of silencing of THRB, and inhibition of function of thyroid hormones in human cancers (JCEM, 2011).

Current Publications

  • Lakshmanan A, Wojcicka A, Kotlarek M, Zhang X, Jazdzewski K, Jhiang SmicroRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.Endocr Relat Cancer in press 11/17/2014
  • Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, Krawczyk M, Jazdzewski KNext generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma.Int J Biochem Cell Biol 53 208-17 8/1/2014
  • Wójcicka A, Czetwertyńska M, Świerniak M, Długosińska J, Maciąg M, Czajka A, Dymecka K, Kubiak A, Kot A, Płoski R, de la Chapelle A, Jażdżewski KVariants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.Genes Chromosomes Cancer 53 516-23 6/1/2014
  • Wojcicka A, de la Chapelle A, Jazdzewski KMicroRNA-related sequence variations in human cancers.Hum Genet 133 463-9 4/1/2014
  • Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R, Hoag K, Wen B, Ploski R, Ringel MD, Kozłowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle ACumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.Thyroid 23 1532-40 12/1/2013
  • He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K, Jendrzejewski J, Jiao H, Hoag K, Wen B, Srinivas M, Waidyaratne G, Wang R, Wojcicka A, Lattimer IR, Stachlewska E, Czetwertynska M, Dlugosinska J, Gierlikowski W, Ploski R, Krawczyk M, Jazdzewski K, Kere J, Symer DE, Jin V, Wang Q, de la Chapelle ACorrection: Ultra-Rare Mutation in Long-Range Enhancer Predisposes to Thyroid Carcinoma with High Penetrance.PLoS One 8(9) 9/10/2013
  • Maciag M, Wiechno W, Gornicka B, Bogdanska M, Koperski L, de la Chapelle A, Jazdzewski K, Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska EIn-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma.J Clin Endocrinol Metab 98 E1401-9 8/1/2013
  • He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, Sebastian N, Wen B, Puch Z, Kalemba M, Stachlewska E, Czetwertynska M, Dlugosinska J, Dymecka K, Ploski R, Krawczyk M, Morrison PJ, Ringel MD, Kloos RT, Jazdzewski K, Symer DE, Vieland VJ, Ostrowski M, Jarząb B, de la Chapelle ASRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.J Clin Endocrinol Metab 98 E973-80 5/1/2013
  • Wojcicka A, Lattimer IR, Stachlewska E, Czetwertynska M, Dlugosinska J, Gierlikowski W, Ploski R, Krawczyk M, Jazdzewski K, Kere J, Symer DE, Jin V, Wang Q, de la Chapelle A, He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K, Jendrzejewski J, Jiao H, Hoag K, Wen B, Srinivas M, Waidyaratne G, Wang RUltra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance.PLoS One 8 e61920 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu